Biosensor analysis of the molecular interactions of pentosan polysulfate and of sulfated glycosaminoglycans with immobilized elastase, hyaluronidase and lysozyme using surface plasmon resonance (SPR) technology.

[1]  M. Goldstein.  Glucosamine sulphate and osteoarthritis , 2001, The Lancet.

[2]  K. Brandt,et al.  Should the initial drug be used to treat osteoarthritis pain be a nonsteroidal antiinflammatory drug? , 2001, The Journal of rheumatology.

[3]  Eric Lejeune,et al.  Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial , 2001, The Lancet.

[4]  Thomas Aigner,et al.  Articular cartilage and changes in Arthritis: Cell biology of osteoarthritis , 2001, Arthritis Research & Therapy.

[5]  Joan C. Woodward,et al.  In Vivo Chondroprotection and Metabolic Synergy of Glucosamine and Chondroitin Sulfate , 2000, Clinical orthopaedics and related research.

[6]  S. Yamada,et al.  Structure and Function of Oversulfated Chondroitin Sulfate Variants , 2000 .

[7]  M. Goldring,et al.  The role of the chondrocyte in osteoarthritis. , 2000, Arthritis and rheumatism.

[8]  D. Felson,et al.  Glucosamine and chondroitin for osteoarthritis: to recommend or not to recommend? , 2000, Arthritis care and research : the official journal of the Arthritis Health Professions Association.

[9]  H Lennernäs,et al.  SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans. , 2000, Journal of medicinal chemistry.

[10]  Laurence Choulier,et al.  Effects on interaction kinetics of mutations at the VH–VL interface of Fabs depend on the structural context , 2000, Journal of molecular recognition : JMR.

[11]  H Roos,et al.  Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. , 2000, Journal of medicinal chemistry.

[12]  M. Hämäläinen,et al.  Biosensor analysis of drug-target interactions: direct and competitive binding assays for investigation of interactions between thrombin and thrombin inhibitors. , 2000, Analytical biochemistry.

[13]  J. Delafuente.  Glucosamine in the treatment of osteoarthritis. , 2000, Rheumatic diseases clinics of North America.

[14]  M. Degenhardt,et al.  Studies on the Structural Variations of Pentosan Polysulfate Sodium (NaPPS) from Different Sources by Capillary Electrophoresis , 2000, Archiv der Pharmazie.

[15]  T. Ciardelli,et al.  Biosensor analysis of the interleukin‐2 receptor complex , 1999, Journal of molecular recognition : JMR.

[16]  P. Ghosh.  Seminars in Arthritis and Rheumatism , 1999 .

[17]  A. Philippi,et al.  Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. , 1999, Military medicine.

[18]  H. Wätzig,et al.  Quality control of pentosane polysulfate by capillary zone electrophoresis using indirect detection. , 1998, Journal of chromatography. A.

[19]  C. C. da Camara,et al.  Glucosamine Sulfate for Osteoarthritis , 1998, The Annals of pharmacotherapy.

[20]  E. Elkin,et al.  Assessing cost-effectiveness analyses in rheumatoid arthritis and osteoarthritis. , 1997, Arthritis care and research : the official journal of the Arthritis Health Professions Association.

[21]  E. Brown.  Neutrophil adhesion and the therapy of inflammation. , 1997, Seminars in hematology.

[22]  R. Moskowitz,et al.  Design and conduct of clinical trials in osteoarthritis: preliminary recommendations from a task force of the Osteoarthritis Research Society. , 1997, The Journal of rheumatology.

[23]  B. Preston,et al.  Purification, characterization, and biosynthesis of bovine cartilage lysozyme isoforms. , 1997, Archives of biochemistry and biophysics.

[24]  T. Hage,et al.  Global and Local Determinants for the Kinetics of Interleukin‐4/Interleukin‐4 Receptor α Chain Interaction , 1996 .

[25]  R. Read,et al.  Systemic use of pentosan polysulphate in the treatment of osteoarthritis. , 1996, The Journal of small animal practice.

[26]  C. Bartolucci,et al.  Inhibition of human leukocyte elastase by chemically and naturally oversulfated galactosaminoglycans. , 1995, Carbohydrate research.

[27]  A. Malmborg,et al.  BIAcore as a tool in antibody engineering. , 1995, Journal of immunological methods.

[28]  A. Conte,et al.  Effects of chondroitin sulfates with different structures on leukemia cells: U-937 cell proliferation and differentiation. , 1993, Leukemia research.

[29]  N. Schachar,et al.  Collagen fibril structure of normal, aging, and osteoarthritic cartilage , 1992, The Journal of pathology.

[30]  Roland W. Moskowitz,et al.  Osteoarthritis: Diagnosis and Medical/Surgical Management , 1992 .

[31]  M. J. Janusz,et al.  Degradation of cartilage matrix proteoglycan by human neutrophils involves both elastase and cathepsin G. , 1991, Journal of immunology.

[32]  A. Ratcliffe,et al.  Variability in the immunochemical quantification of keratan sulphate in human and bovine cartilage proteoglycans. , 1990, Biochemical Society transactions.

[33]  Y. Okada,et al.  Activation of matrix metalloproteinase 3 (stromelysin) and matrix metalloproteinase 2 (‘gelatinase’) by human neutrophil elastase and cathepsin G , 1989, FEBS letters.

[34]  W. Hornebeck,et al.  Influence of heparin fragments on the biological activities of elastase(s) and alpha 1 proteinase inhibitor. , 1988, Biochemical pharmacology.

[35]  D. Woolley,et al.  Susceptibility of cartilage collagens type II, IX, X, and XI to human synovial collagenase and neutrophil elastase. , 1988, European journal of biochemistry.

[36]  J. Travis,et al.  Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases , 1988, FEBS letters.

[37]  L. Joosten,et al.  Elastase secreted by activated polymorphonuclear leukocytes causes chondrocyte damage and matrix degradation in intact articular cartilage , 1988, Agents and Actions.

[38]  P. Ghosh,et al.  Laboratory evaluation of antiarthritic drugs as potential chondroprotective agents. , 1987, Seminars in arthritis and rheumatism.

[39]  R. Moskowitz,et al.  Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. , 1986, Arthritis and rheumatism.

[40]  M. Malaise,et al.  Measurement of proteoglycans, elastase, collagenase and protein in synovial fluid in inflammatory and degenerative arthropathies , 1985, Clinical Rheumatology.

[41]  D. Lewis,et al.  Neutral protease, collagenase and elastase activities in synovial fluids from arthritic patients , 1984, Agents and Actions.

[42]  A. Baici,et al.  Interaction between human leukocyte elastase and chondroitin sulfate. , 1984, Chemico-biological interactions.

[43]  C. Handley,et al.  Changes in proteoglycan biosynthesis following leukocyte elastase treatment of bovine articular cartilage in culture. , 1984, Arthritis and rheumatism.

[44]  P. Ghosh,et al.  The interaction of pentosan polysulphate (SP54) with human neutrophil elastase and connective tissue matrix components. , 1983, Chemico-biological interactions.

[45]  A. Baici,et al.  Inhibition of human elastase from polymorphonuclear leucocytes by gold sodium thiomalate and pentosan polysulfate (SP-54). , 1981, Biochemical pharmacology.

[46]  J. McDonald,et al.  Degradation of fibronectin by human leukocyte elastase. Release of biologically active fragments. , 1980, The Journal of biological chemistry.

[47]  A. Kang,et al.  Degradation of type IV (basement membrane) collagen by a proteinase isolated from human polymorphonuclear leukocyte granules. , 1980, The Journal of biological chemistry.

[48]  C. Malemud,et al.  HUMAN POLYMORPHONUCLEAR LEUKOCYTE ELASTASE AND CATHEPSIN G MEDIATE THE DEGRADATION OF LAPINE ARTICULAR CARTILAGE PROTEOGLYCAN * , 1975, Annals of the New York Academy of Sciences.

[49]  A. Baici,et al.  Action of collagenase and elastase from human polymorphonuclear leukocytes on human articular cartilage , 2004, Rheumatology International.

[50]  L. Joosten,et al.  Degradation of cartilage proteoglycans by elastase is dependent on charge-mediated interactions , 2004, Rheumatology International.

[51]  H. Burkhardt,et al.  Lysosomal elastase: Effect on mechanical and biochemical properties of normal cartilage, inhibition by polysulfonated glycosaminoglycan, and binding to chondrocytes , 2004, Rheumatology International.

[52]  K. Fehr,et al.  Degradation in vivo of articular cartilage in rheumatoid arthritis and juvenile chronic arthritis by cathepsin G and elastase from polymorphonuclear leukocytes , 2004, Rheumatology International.

[53]  A. Baici,et al.  Degradation in vivo of articular cartilage in rheumatoid arthritis by leucocyte elastase from polymorphonuclear leucocytes , 2004, Rheumatology International.

[54]  B. Mazières,et al.  Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. , 2001, The Journal of rheumatology.

[55]  M. Ochi,et al.  Alteration of collagen network and negative charge of articular cartilage surface in the early stage of experimental osteoarthritis , 2001, Archives of Orthopaedic and Trauma Surgery.

[56]  Thomas J. Schnitzer,et al.  Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update , 2000 .

[57]  E. Badley,et al.  Arthritis and the aging population: projections of arthritis prevalence in Canada 1991 to 2031. , 1998, The Journal of rheumatology.

[58]  E. Buzás,et al.  Mapping of arthritogenic/autoimmune epitopes of cartilage aggrecans in proteoglycan-induced arthritis. , 1995, Scandinavian journal of rheumatology. Supplement.

[59]  P. Venge,et al.  The inflammatory process : an introduction to the study of cellular and humoral mechanisms , 1981 .